146 related articles for article (PubMed ID: 23994265)
1. Withanone as an inhibitor of survivin: a potential drug candidate for cancer therapy.
Wadegaonkar VP; Wadegaonkar PA
J Biotechnol; 2013 Oct; 168(2):229-33. PubMed ID: 23994265
[TBL] [Abstract][Full Text] [Related]
2. Ashwagandha derived withanone targets TPX2-Aurora A complex: computational and experimental evidence to its anticancer activity.
Grover A; Singh R; Shandilya A; Priyandoko D; Agrawal V; Bisaria VS; Wadhwa R; Kaul SC; Sundar D
PLoS One; 2012; 7(1):e30890. PubMed ID: 22303466
[TBL] [Abstract][Full Text] [Related]
3. The functional repertoire of survivin's tails.
Wheatley SP
Cell Cycle; 2015; 14(2):261-8. PubMed ID: 25607650
[TBL] [Abstract][Full Text] [Related]
4. Theoretical study of the intermolecular recognition mechanism between Survivin and substrate based on conserved binding mode analysis.
Wu C; Mao L; Huang X; Fu W; Cai X; Cai Y; Shen L; Ye X
J Mol Graph Model; 2018 Aug; 83():53-63. PubMed ID: 29772403
[TBL] [Abstract][Full Text] [Related]
5. Survivin as a Potential Target for Cancer Therapy.
Soleimanpour E; Babaei E
Asian Pac J Cancer Prev; 2015; 16(15):6187-91. PubMed ID: 26434815
[TBL] [Abstract][Full Text] [Related]
6. Treat cancers by targeting survivin: just a dream or future reality?
Coumar MS; Tsai FY; Kanwar JR; Sarvagalla S; Cheung CH
Cancer Treat Rev; 2013 Nov; 39(7):802-11. PubMed ID: 23453862
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological studies of survivin dimerization modulators that prolong mitotic cycle.
Chettiar SN; Cooley JV; Park IH; Bhasin D; Chakravarti A; Li PK; Li C; Jacob NK
Bioorg Med Chem Lett; 2013 Oct; 23(19):5429-33. PubMed ID: 23968825
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design and molecular profiling of Smac-mimetics selective for cellular IAPs.
Corti A; Milani M; Lecis D; Seneci P; de Rosa M; Mastrangelo E; Cossu F
FEBS J; 2018 Sep; 285(17):3286-3298. PubMed ID: 30055105
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis and Structure-Activity Relationship Studies of Novel Survivin Inhibitors with Potent Anti-Proliferative Properties.
Xiao M; Wang J; Lin Z; Lu Y; Li Z; White SW; Miller DD; Li W
PLoS One; 2015; 10(6):e0129807. PubMed ID: 26070194
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle-mediated inhibition of survivin to overcome drug resistance in cancer therapy.
Wang S; Xu Y; Chan HF; Kim HW; Wang Y; Leong KW; Chen M
J Control Release; 2016 Oct; 240():454-464. PubMed ID: 27091696
[TBL] [Abstract][Full Text] [Related]
11. Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.
Premkumar DR; Jane EP; Pollack IF
Cancer Biol Ther; 2015; 16(2):233-43. PubMed ID: 25482928
[TBL] [Abstract][Full Text] [Related]
12. Survivin in survival of hepatocellular carcinoma.
Su C
Cancer Lett; 2016 Sep; 379(2):184-90. PubMed ID: 26118774
[TBL] [Abstract][Full Text] [Related]
13. Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway.
Huang KF; Zhang GD; Huang YQ; Diao Y
Int Immunopharmacol; 2012 Feb; 12(2):334-41. PubMed ID: 22182776
[TBL] [Abstract][Full Text] [Related]
14. High-throughput screening for Survivin and Borealin interaction inhibitors in hepatocellular carcinoma.
Yue L; Li L; Li D; Yang Z; Han S; Chen M; Lan S; Xu X; Hui L
Biochem Biophys Res Commun; 2017 Mar; 484(3):642-647. PubMed ID: 28153734
[TBL] [Abstract][Full Text] [Related]
15. Survivin Small Molecules Inhibitors: Recent Advances and Challenges.
Albadari N; Li W
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771042
[TBL] [Abstract][Full Text] [Related]
16. Blocking protein kinase C signaling pathway: mechanistic insights into the anti-leishmanial activity of prospective herbal drugs from Withania somnifera.
Grover A; Katiyar SP; Jeyakanthan J; Dubey VK; Sundar D
BMC Genomics; 2012; 13 Suppl 7(Suppl 7):S20. PubMed ID: 23281834
[TBL] [Abstract][Full Text] [Related]
17. [Role of survivin in mitosis].
Wolanin K; Piwocka K
Postepy Biochem; 2007; 53(1):10-8. PubMed ID: 17718383
[TBL] [Abstract][Full Text] [Related]
18. Piperine derivatives as potential inhibitors of Survivin: An in silico molecular docking.
Sattarinezhad E; Bordbar AK; Fani N
Comput Biol Med; 2015 Aug; 63():219-27. PubMed ID: 26093789
[TBL] [Abstract][Full Text] [Related]
19. An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancy.
Zangemeister-Wittke U; Simon HU
Cell Cycle; 2004 Sep; 3(9):1121-3. PubMed ID: 15326382
[TBL] [Abstract][Full Text] [Related]
20. Survivin: A molecular biomarker in cancer.
Jaiswal PK; Goel A; Mittal RD
Indian J Med Res; 2015 Apr; 141(4):389-97. PubMed ID: 26112839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
